404O - The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
Cancer Aetiology, Epidemiology, Prevention
Melanoma and other Skin Tumours
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix126-ix129. 10.1093/annonc/mdw589|
B. Lian1, C. Cui1, L. Zhou1, X. Song2, X. Zhang3, D. Wu4, L. Si1, Z. Chi1, X. Sheng1, C.M. Balch5, J. Guo1
We examined whether mucosal melanomas are different in their clinical course and patterns of metastases when arising from different anatomic sites. Our hypothesis was that metastatic behavior would differ from primary mucosal melanomas at different anatomical sites.
Clinical and pathological data from 706 patients were compared for their stage distribution, patterns of metastases, and cKIT/BRAF mutation status.
The anatomic sites of the primary mucosal melanomas were from the lower GI tract (26.5%), nasal cavity and paranasal sinuses (23%), gynecological sites (22.5%), oral cavity (15%), urological sites (5%), upper GI tract (5%), and other sites (3.0%). At initial diagnosis, 14.5% were stage I disease, 41% Stage II, 21.5% Stage III, and 23.0% stage IV. Predominant metastatic sites were regional lymph nodes (21.5%), lung (21%), liver (18.5%), and distant nodes (9%). Oral cavity mucosal melanoma had a higher incidence of regional nodal metastases (31.7% vs19.8%, p = 0.009), and a higher incidence of lung metastases (32.5%vs18.5%, p = 0.007) compared to other primary mucosal melanomas. There was a 10% incidence of cKIT mutation and 12% BRAF mutation.
The large sample size allows, for the first time, a comparison of primary melanoma stage and patterns of metastases across anatomical sites. With few exceptions, we did not identify any differences in metastatic distribution when comparing data across presenting stages of disease, incidence of nodal and distant metastases, or the site of predilection of distant metastases. These findings suggest that clinical trials involving mucosal melanomas and the administration of systemic therapy can be applied equally to mucosal melanomas regardless of their primary anatomic site.
Clinical trial indentification
Legal entity responsible for the study
This work was supported by grants from the Major State Basic Research Development Program of China (2013CB911004), New Century Excellent Talents in University (NCET-13-0007), Beijing Natural Science Foundation (7152033, 7154187, 7164244), Beijing Talents Fund (2014000021223ZK26), Beijing Baiqianwan Talents Project, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support (ZYLX201603), Beijing Municipal Science & Technology Commission (Z151100003915074).
All authors have declared no conflicts of interest.